CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies

Lignende værker

• An exploration of the initiation time and patient selection of PD-1 inhibitors/PD-1 inhibitors combined with chemotherapy as salvage therapy in R/R DLBCL patients after anti-CD19-CAR T-cell therapy
  af: Xin Li, et al.
  Udgivet: (2025-06-01)
• Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer
  af: Chen, Cong, et al.
  Udgivet: (2021)
• Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy
  af: Perna, Fabiana, et al.
  Udgivet: (2016)
• CD19/CD22 Dual‐Targeted CAR‐T Therapy Active in Relapsed/Refractory DLBCL
  Udgivet: (2020)
• CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy
  af: Thapa, Bicky, et al.
  Udgivet: (2020)